Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF JULY 31, 2015 FBO #4998
SPECIAL NOTICE

A -- Development of Multivalent Vaccine Candidates for Filovirus and Lassa Fever - NOT-AI-15-049

Notice Date
7/29/2015
 
Notice Type
Special Notice
 
NAICS
541711 — Research and Development in Biotechnology
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 5601 Fishers Lane, 3rd Floor, MSC 9821, Bethesda, Maryland, 20892, United States
 
ZIP Code
20892
 
Solicitation Number
NOT-AI-15-049
 
Archive Date
9/19/2015
 
Point of Contact
Edward Shane Ryan, Phone: 240-669-5126, Aileene Mitchell Ford, Phone: 301-496-7288
 
E-Mail Address
ryanes@niaid.nih.gov, aileene.mitchellford@nih.gov
(ryanes@niaid.nih.gov, aileene.mitchellford@nih.gov)
 
Small Business Set-Aside
N/A
 
Description
Request for Information (RFI): Development of Multivalent Vaccine NIAID is seeking information from pharmaceutical and biopharmaceutical product developers on multivalent vaccines and rapidly adaptable vaccine platform technologies against filoviruses (Ebola, Sudan, and Marburg); candidate vaccines may also include a component that confers protection against Lassa Fever. The primary focus of this RFI is to gather information about multivalent filovirus vaccine candidates (with a Lassa Fever vaccine component if feasible) that at a minimum have shown efficacy in nonhuman primate disease models for at least one of the filovirus components. NIAID is also seeking information about any multivalent filovirus vaccine candidates that incorporates technological enhancements. Examples of technological enhancements include but are not limited to any of the following: vaccine presentations or formulations that are stable without the need for cold chain; rapid onset of protective immunity that will permit a prophylaxis indication in a post-event scenario; minimal doses to achieve protection; reasonable complexity of vaccine components (e.g., fewer individual viral constructs are preferable); non-parenteral routes of delivery; needle-free delivery; addressing issues such as anti-vector immunity and vaccine interference often seen with multivalent vaccines; comorbidities (e.g., pathogen burdens) and immunological attributes of individuals in Viral Hemorrhagic Fever endemic areas; and maturity of immune assays that may be used to identify correlates of protection. The emphasis of this RFI is to gather information on multivalent filovirus vaccines, preferably ones that include technological enhancements. Multivalent filovirus vaccine candidates that also incorporate a component to confer protection against Lassa Fever are of interest.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIAID/NOT-AI-15-049/listing.html)
 
Record
SN03815122-W 20150731/150729235812-b88feab43dbd83a8cd6ce8a9588bc33d (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.